Universal Health Insurance does not exist in the United States for two reasons: (1) there is a general unwillingness to dismantle the historically grown framework of the world’s most complex mix of public and private sector health coverage and (2) mere cost considerations. The first concern can be abated by establishing a Universal Health Insurance system which retains many or most of the historically grown infrastructure. Cost containment of such a reform is addressed herein in that the two proposed pathways comprise either (1) a leveled solution through Medicare-expansion for the uninsured only or (2) a more complex solution through a national, 2-tier healthcare system for all Americans. Both pathways are based on solid financing without major tax increases by using existing and/or yet untapped funding sources. The insurance consequences for both options are assessable. They are minor for the Medicare-expansion and more wide-ranging, yet also achievable, for a national, 2-tier healthcare system. Universal Health Insurance must no longer be an illusion that continues to haunt our society in the 21st century.
For insurance medicine to be recognized and accepted by its peers in the medical community as a viable medical specialty, 2 elements are necessary: a core, evidence-based knowledge competency, and a peer-reviewed scientific journal to exhibit our science of risk selection not only to members but also to the national and international medical community. Our website states, the American Academy of Insurance Medicine (AAIM) believes that medical science, especially the science of mortality and morbidity is the basis for the practice of insurance medicine. Our Mission Statement further states, “our focus is education and research involving the
To demonstrate a method which is being used to apportion between risk factors for occupationally related disease and compensate individuals with multiple risk factors. The application to individuals will be demonstrated for varicose veins. The National Insurance Institute (NII) is tasked with compensating work related injuries and illness in Israel. Population attributable fraction (PAF) has been utilized in order to estimate the amount of disease that can potentially be eliminated in a population through the elimination of individual risk factors. PAF is based on relative risks and the prevalence of these risks. A review of the medical literature consisting of epidemiological studies of varicose veins and its multiple risk factors was conducted, with special attention to prolonged occupational standing. Summary, weighted, relative risks were calculated for eight different risk factors. The proposed formula then allowed for apportioning among those risk factors in the individual. The findings of the current study indicate that prolonged standing may be associated with the presence of varicose veins, however in light of the multiple other risk factors associated, its overall contribution is generally minor. Apportionment among multiple risk factors for varicose veins can be accomplished mathematically in individuals. This application is being applied successfully for other diseases as well.Objective.—
Background.—
Methods.—
Results.—
Conclusion.—
Little evidence based information exists in the medical literature on the mortality of abusers of anabolic androgenic steroids. These individuals range from competitive athletes and body builders to those whose who use physician prescribed mega-doses. Life insurance medical directors have little guidance on how to underwrite these individuals when presented with their applications. A recent article presented a Kaplan-Meir mortality curve accompanied with a control population demonstrating the mortality of these individuals over a 13-year period. Users of non-physiologic doses of anabolic androgenic steroids experience a mortality about two times the expected mortality of the control population. They should be underwritten with ratings commensurate with their anabolic androgenic steroid abuse and demonstrated mortality.
In principle, it is generally accepted that DNA methylation measures can be used to predict mortality. However, as of yet, no epigenetic metric has been successfully incorporated into underwriting procedures. In part, this failure results from the relative incompatibility of many DNA methylation measures with conventional underwriting practices. To test the ability of previously established epigenetic markers of smoking, drinking and diabetes to standard lipid-based approaches for predicting mortality. We constructed a series of Cox proportional hazards models for mortality using clinical data and DNA methylation data from 4 previously described loci from the Framingham Heart Study. The incorporation of vital signs, standard lipid and diabetes laboratory assessments to a base model consisting of age and sex only modestly increased prediction of mortality from 0.732 to 0.741 area under the curve (AUC). However, the addition of epigenetic marker information for smoking and drinking to the base model markedly increased prediction (AUC=0.787) while the addition of epigenetic marker for diabetes increased prediction even further (AUC=0.792). These results demonstrate the potential of simple interpretable, epigenetic models to predict mortality in a manner compatible with standard underwriting procedures. Potentially, this epigenetic approach using rapid methylation sensitive digital PCR procedures that can utilize saliva or whole blood DNA would increase prediction power even further while facilitating more accurate accelerated underwriting assessments of mortality.Background.—
Objective.—
Method.—
Results.—
Conclusion.—
Many COVID-19 survivors report protracted symptoms, sometimes lasting 3 years or more. These are collectively called post-acute sequelae of SARS-CoV-2 infection (PASC), or long Covid.1–4 In addition, several common diseases appear to be diagnosed more frequently following COVID-19 infection. Amongst these, cardiopulmonary disorders predominate, but diseases of many organ systems have been reported. Case reports of de novo autoimmune disorders appeared early during the pandemic. In 2023, 5 large international cohort studies provided further evidence that autoimmune disorders may be more common. Dysregulated immune responses have been a consistent feature of SARS-CoV-2 infection. OneIncidence Of Autoimmune Diseases
The basic definitions of obstructive sleep apnea (OSA), its epidemiology, its clinical features and complications, and the morbidity and mortality of OSA are discussed. Included in this treatise is a discussion of the various symptomatic and polysomnographic phenotypes of COPD that may enable better treatment and impact mortality in persons with OSA. The goal of this article is to serve as a reference for life and disability insurance company medical directors and underwriters when underwriting an applicant with probable or diagnosed sleep apnea. It is well-referenced (133 ref.) allowing for more in-depth investigation of any aspect of sleep apnea being queried.
The first pancreas transplant was performed by William Kelly and Richard Lillehei at the University of Minnesota on December 17, 1966, but high graft failure rates initially marred the field of pancreas transplantation due to technical and immunological complications. For that reason, until the early 1980s, less than 100 pancreas transplants per year were performed worldwide. With major improvements in surgical techniques and immunosuppressive therapy that number had increased to 1000 pancreas transplants per year in the early 1990s and to >2000 pancreas transplants per year after the turn of the millennium. By the end of 2020, more than 63,000
The National Academy of Sciences Institute of Medicine (IOM) focuses on specific features to make the diagnosis of myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS). Symptoms should be present for at least 6 months and have moderate, substantial, or severe intensity at least half the time. In addition to fatigue, other necessary criteria include post-exertional malaise, unrefreshing sleep, cognitive impairment, and orthostatic-related symptoms. Although complaints of chronic fatigue are common, relatively few (75 to 267 cases per 100,000 persons, vs 1775 to 6321 cases per 100,000 persons in patients with fatigue of 6 months duration but nothing more) satisfy
Moral hazard is well known to life insurance underwriters and medical directors to increase the risk of adverse consequences to insured individuals. The underwriting investigation of proposed insureds at time of policy issue is done to ensure no likely moral hazard exists. However, not all situations involving moral hazard may be identified at time of underwriting and policy issue, and may only be identified at time of claim. Three cases that were underwritten for life expectancies in legal matters are described here as examples of moral hazard identified at time of severe injury and/or death. All three of these cases involved a woman who manipulated her male partner into situations that increased the man’s risk of severe injury and/or death to the woman’s financial benefit. Such “black widows” made a great deal of effort over an extensive period of time to ensure that the moral hazard set up for their male partners resulted in a substantial financial windfall through litigation. The moral hazard set up by a black widow thus can be considered by the life insurance industry as sufficiently anti-selective and speculative to deny a claim at any time after policy issue.